Credit Suisse Group Reaffirms Hold Rating for Spark Therapeutics (ONCE)

Share on StockTwits

Credit Suisse Group reaffirmed their hold rating on shares of Spark Therapeutics (NASDAQ:ONCE) in a report published on Friday. They currently have a $44.00 target price on the biotechnology company’s stock.

Other equities analysts have also issued reports about the stock. Cantor Fitzgerald reiterated an overweight rating and issued a $80.00 target price (down from $103.00) on shares of Spark Therapeutics in a report on Thursday, January 10th. Zacks Investment Research lowered shares of Spark Therapeutics from a buy rating to a hold rating in a report on Saturday, October 13th. B. Riley upgraded shares of Spark Therapeutics from a neutral rating to a buy rating and upped their price objective for the stock from $68.00 to $71.00 in a report on Wednesday, November 7th. Raymond James restated a buy rating on shares of Spark Therapeutics in a report on Monday, November 26th. Finally, Mizuho decreased their price objective on shares of Spark Therapeutics to $62.00 and set a buy rating on the stock in a report on Wednesday, November 7th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have issued a buy rating to the company. Spark Therapeutics presently has a consensus rating of Buy and an average price target of $65.20.

ONCE opened at $47.44 on Friday. The stock has a market cap of $1.79 billion, a P/E ratio of -6.22 and a beta of 2.06. Spark Therapeutics has a twelve month low of $34.53 and a twelve month high of $96.59. The company has a current ratio of 10.71, a quick ratio of 10.36 and a debt-to-equity ratio of 0.09.

Large investors have recently modified their holdings of the stock. Pearl River Capital LLC acquired a new stake in Spark Therapeutics during the 4th quarter worth $31,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Spark Therapeutics during the 3rd quarter worth $122,000. Quantamental Technologies LLC acquired a new stake in Spark Therapeutics during the 4th quarter worth $126,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Spark Therapeutics by 16.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,460 shares of the biotechnology company’s stock worth $135,000 after purchasing an additional 485 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Spark Therapeutics by 103.4% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,718 shares of the biotechnology company’s stock worth $141,000 after purchasing an additional 1,890 shares during the period.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Recommended Story: Why is the ROA ratio important?

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply